Telomir Pharmaceuticals (NASDAQ:TELO) Upgraded at Zacks Research

Zacks Research upgraded shares of Telomir Pharmaceuticals (NASDAQ:TELO) to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

Several other analysts have also recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating for the company. Wall Street Zen upgraded Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Telomir Pharmaceuticals Price Performance

Shares of Telomir Pharmaceuticals stock opened at $1.32 on Wednesday. Telomir Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $4.81. The business has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.36. The company has a market capitalization of $45.38 million, a P/E ratio of -4.00 and a beta of -0.66.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. As a group, research analysts expect that Telomir Pharmaceuticals will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TELO. Praetorian Wealth Management Inc. acquired a new stake in Telomir Pharmaceuticals in the third quarter valued at $28,000. OneDigital Investment Advisors LLC raised its stake in Telomir Pharmaceuticals by 64.3% during the third quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock valued at $32,000 after buying an additional 9,000 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Telomir Pharmaceuticals during the second quarter valued at approximately $33,000. World Investment Advisors bought a new position in Telomir Pharmaceuticals during the 4th quarter worth approximately $47,000. Finally, XTX Topco Ltd acquired a new position in shares of Telomir Pharmaceuticals in the 4th quarter worth approximately $53,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.